Compare PRLB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRLB | TBPH |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 993.7M |
| IPO Year | 2012 | N/A |
| Metric | PRLB | TBPH |
|---|---|---|
| Price | $53.65 | $20.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $53.00 | $27.80 |
| AVG Volume (30 Days) | 124.7K | ★ 370.5K |
| Earning Date | 02-06-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | 0.58 |
| Revenue | ★ $518,384,000.00 | $80,327,000.00 |
| Revenue This Year | $7.07 | $70.78 |
| Revenue Next Year | $4.87 | N/A |
| P/E Ratio | $90.17 | ★ $35.74 |
| Revenue Growth | 2.82 | ★ 27.12 |
| 52 Week Low | $29.59 | $7.90 |
| 52 Week High | $56.60 | $21.03 |
| Indicator | PRLB | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 60.45 |
| Support Level | $52.95 | $19.53 |
| Resistance Level | $56.60 | $21.03 |
| Average True Range (ATR) | 1.64 | 0.83 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 51.68 | 76.45 |
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).